title: [Dementia of the Alzheimer type: non-drug and drug therapy].
abstract: The optimal management of Alzheimer's disease (AD) involves a close alliance with AD caregivers and requires early diagnosis, multimodal management, including non-drug and drug interventions, and multispecialty care. Non-pharmacological approaches such as cognitive stimulation programs mostly benefit behavior and psychiatric symptoms in dementia patients. Pharmacologic management of AD consists of eliminating therapeutic redundancies and potentially deleterious medications (Beers Criteria). A pharmacologic foundation of Ginkgo Biloba and combination therapy with a cholinesterase inhibitor and memantine reduces decline in cognition and function, decreases and/or delays the emergence and impact of neuropsychiatric symptoms, postpones institutionalization, and works best when appropriately instituted early and maintained. Despite an existing reimbursement limitation by the health-insurance system in Switzerland, the combination of cholinesterase inhibitor and memantine is possible within the admitted MMSE ranges.
authors: Felix Platter-Spital, Universitäre Altersmedizin, Basel.
authors: Reto W
authors: RW
authors: Kressig
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D001521:Behavior Therapy; D017028:Caregivers / Q000523:psychology; D003131:Combined Modality Therapy; D003299:Cooperative Behavior; D017281:Cost of Illness; D042241:Early Diagnosis; D006801:Humans; D033183:Interdisciplinary Communication; D018697:Nootropic Agents / Q000627:therapeutic use*; D010353:Patient Education as Topic; D013557:Switzerland
chemical_list: D018697:Nootropic Agents